Of note, 3 genes of interest were identified as having intron retention in both OPM2 and XG7 cells: 1) HELLS, encoding a lymphoid-specific helicase involved in chromatin remodelling, 2) SLAMF7, encoding the CD319 surface antigen which is targeted by the anti-MM drug elotuzumab and 3) WHSC1/MMSET, involved in the chromosomal translocation t (4; 14). This evidence concerns the gene HELLS and Miyoshi myopathy.